Literatur
- 1
Castillo J, Leira R, Carcia M M, Serena J S, Blanco M, Davalos A.
Blood pressure decrease during the acute phase of ischemic stroke is associated with
brain injury and poor stroke outcome.
Stroke.
2004;
35
520-527
- 2
Dahlof B, Devereux R B, Kjeldsen S E. et al, for the LIFE study group .
Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction
in hypertension study (LIFE): a randomized trial against atenolol.
Lancet.
2002;
359
995-1003
- 3
Gueyffier F. et al, for the INDANA (Individual Data Analysis of Antihypertensive intervention
trial) Project Collaborators .
Effect of antihypertensive treatment in patients having already suffered from stroke:
gathering the evidence.
Stroke.
1997;
28
2557-2562
- 4
International Society of Hypertension Writing Group .
International Society ofHypertension (ISH): statement on the management of blood pressure
in acute stroke.
J Hypertension.
2003;
21
665-672
- 5
Leonardi-Bee J, Bath P, Phillips S, Sandercock P. IST Collaborative Group .
Blood pressure and clinical outcomes in the International Stroke Trial.
Stroke.
2002;
33
1315-1320
- 6
Lindholm L H, Carlberg B, Samuelsson O.
Should beta blockers remain first choice in the treatment of primary hypertension?
A meta-analysis.
Lancet.
2005;
366
1545-1553
- 7
Perindopril Protection Against Recurrent Stroke Study (PROGRESS) Collaborative Group
.
Randomises trial of a perindopril-based blood-pressure-lowering regimen among 6105
individuals with previous stroke or transient ischaemic attack.
Lancet.
2001;
358
1033-1041
- 8
Rashid P, Leonardi-Bee J, Bath P.
Blood pressure reduction and secondary prevention of stroke and other vascular events.
A systematic review.
Stroke.
2003;
34
2741-2749
- 9
Rodgers A, MacMahon S, Gamble G, Slattery J, Sandercock P, Warlow C.
Blood pressure and risk of stroke in patients with cerebrovascular disease: the United
Kingdom transient ischaemic attack collaborative group (letter).
BMJ.
1996;
313
147
- 10
Schrader J, Lüders S, Kulschewski A JB, Zidek W, Treib J, Einhäupl K, Diener H C,
Dominiak P. On behalf of the ACESS study group .
Evaluation of acute candesartan cilexetil therapy in stroke survivors.
Stroke.
2003;
34
1699-1703
- 11
Schrader J, Lüders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P,
Diener H C. for the MOSES Study Group .
Morbidity and mortality after stroke. Eprosartan compared with nitrendipine for secondary
prevention (MOSES).
Stroke.
2005;
36
1218-1226
- 12
Wachtell K. et al .
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent
stroke compared to atenolol. The losartan intervention for end point reduction in
hypertension (LIFE) study.
J Am Coll Cardiol.
2005;
45
712-719
- 13
Wachtell K. et al .
Cardiovascular morbidity and mortality in hypertensive patients with a history of
atrial fibrillation. The Losartan Intervention For End point reduction in hypertension
(LIFE) study.
J Am Coll Cardiol.
2005;
45
705-711
- 14
Wahlgren N G, McMahon D G, DeKeyser J. et al .
Intravenous nimodipine west. European stroke trial (IN-WEST) of nimodipine in the
treatment of acute ischemic stroke.
Cerebrovasc Dis.
1994;
4
204-210
- 15
Willmot M, Leonardi-Bee J, Bath P MW.
High blood pressure in acute stroke and subsequent outcome.
Hypertension.
2004;
43
18-24
- 16
Nabavi D G, Ringelstein E B.
Akutbehandlung der Hypertonie bei Schlaganfall - contra.
Dtsch med Wochenschr.
2005;
130
2663
- 17
Deutsche Gesellschaft für Neurologie .
Ischämischer Schlaganfall: Akuttherapie.
http:www.dgn.org.
Prof. Dr. Joachim Schrader
Medizinische Klinik, St-Josefs-Hospital Cloppenburg
Krankenhausstraße 13
49661 Cloppenburg
Telefon: 04471/162951
Fax: 04471/162970
eMail: j.schrader@kh-clp.de
